The New York Times > Business > Media & Advertising > Dispute Puts a Medical Journal Under Fire
By BARRY MEIER (NYT, Published: January 17, 2005)
Past year was an especially bad one for the pharmaceutical industry, which experienced controversies over how drug studies are disclosed and the implosion of the painkiller Vioxx. Now, as a result of the recent publication of an article about the antidepressant Prozac, it appears that the staid, usually methodical world of medical journals could suffer its own black eye.
On New Year's Day, the British medical journal BMJ published a news article suggesting that "missing" documents from a decade-old lawsuit indicated that Eli Lilly & Company, the maker of Prozac, had minimized data about the drug's risks of causing suicidal or violent behavior....
De: Maria Inês Reinert Azambuja [mailto:miazambuja@terra.com.br]
Enviada em: segunda-feira, 17 de janeiro de 2005 09:07
Assunto: do NYT de hoje...
Olhe só esta!
"You put something out on the newswire with the imprimatur of a medical journal and people think it is fact," said Dr. Alan Brier, the chief medical officer of Eli Lilly, which is based in Indianapolis. NYT de 17/1/2005
Ele estava se defendendo da acusação de que a Lilly sabia dos riscos de comportamento violento do Prozac há 10 anos, que saiu no BMJ e depois na imprensa.
Mas ele deve saber muito bem sobre o que está falado... É isto que a indústria farmacêutica faz o tempo todo!
Maria Inês
No comments:
Post a Comment